Nano-solutions from new cancer treatments
Cancer is not a disease that is easy to treat, but many innovative European companies are researching and developing new types of treatments to increase survival chances and decrease side effects. Take MagForce, a German company that is among the early developers of nanotechnology-based new cancer treatments.
The technology is based on an injection of iron oxide nanoparticles into the solid tumor. Then, MagForce’s therapy device, the NanoActivator, is used to treat the affected area with an alternating magnetic field. “This alternating magnetic causes that the nanoparticles generate heat, and this heat either destroys the tumor cells directly or sensitizes them to any concomitant therapy e.g. radio- or chemotherapy,” says Dr. Ben Lipps, Magforce’s CEO. “The body then discharges these devitalized cells in a natural process.”
MagForce’s NanoTherm therapy is the first and only nanotechnology-based therapy with European regulatory approval (CE conformity marking) for the treatment of brain tumors. Patients are commercially treated in Berlin, Münster, and Cologne.
MagForce is now working on its roll-out plan, to make NanoTherm therapy available outside Germany. Next target countries are Poland and Italy, aided by a EUR 35 million EIB loan under the European Fund for Strategic Investments, which combines EIB financing with an EU budget guarantee.
“The EIB contribution is vital to carry on our European roll-out plan,” Lipps says.